Autism - Pipeline Review, H2 2018

Date: July 10, 2018
Pages: 151
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until August 3, 2018!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A5CCB99A791EN
Leaflet:

Download PDF Leaflet

Autism - Pipeline Review, H2 2018
Autism - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Pipeline Review, H2 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 3, 21, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics Development
Tourette Syndrome - Therapeutics Assessment
Tourette Syndrome - Companies Involved in Therapeutics Development
Tourette Syndrome - Drug Profiles
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Autism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Autism - Pipeline by 4D Pharma PLC, H2 2018
Autism - Pipeline by AgeneBio Inc, H2 2018
Autism - Pipeline by APeT Holding BV, H2 2018
Autism - Pipeline by Bantam Pharmaceutical LLC, H2 2018
Autism - Pipeline by BioHealthonomics Inc, H2 2018
Autism - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2018
Autism - Pipeline by Coronis NeuroSciences Ltd, H2 2018
Autism - Pipeline by Curemark LLC, H2 2018
Autism - Pipeline by Evgen Pharma Plc, H2 2018
Autism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Autism - Pipeline by GW Pharmaceuticals Plc, H2 2018
Autism - Pipeline by Heptares Therapeutics Ltd, H2 2018
Autism - Pipeline by Immuron Ltd, H2 2018
Autism - Pipeline by Intra-Cellular Therapies Inc, H2 2018
Autism - Pipeline by Leading BioSciences Inc, H2 2018
Autism - Pipeline by MedDay SA, H2 2018
Autism - Pipeline by Omeros Corp, H2 2018
Autism - Pipeline by OptiNose US Inc, H2 2018
Autism - Pipeline by Ovensa Inc, H2 2018
Autism - Pipeline by RespireRx Pharmaceuticals Inc, H2 2018
Autism - Pipeline by Reviva Pharmaceuticals Inc, H2 2018
Autism - Pipeline by Sumitomo Chemical Co Ltd, H2 2018
Autism - Dormant Projects, H2 2018
Autism - Dormant Projects, H2 2018 (Contd.1), H2 2018
Autism - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Autism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

4D Pharma PLC
AgeneBio Inc
APeT Holding BV
Bantam Pharmaceutical LLC
BioHealthonomics Inc
BrainStorm Cell Therapeutics Inc
Coronis NeuroSciences Ltd
Curemark LLC
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
GW Pharmaceuticals Plc
Heptares Therapeutics Ltd
Immuron Ltd
Intra-Cellular Therapies Inc
Leading BioSciences Inc
MedDay SA
Omeros Corp
OptiNose US Inc
Ovensa Inc
RespireRx Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Sumitomo Chemical Co Ltd
Skip to top


Omeros Corporation - Product Pipeline Review - 2016 US$ 1,200.00 Aug, 2016 · 115 pages
Saniona AB - Product Pipeline Review - 2016 US$ 1,200.00 Aug, 2016 · 55 pages
Anal Cancer - Pipeline Review, H1 2018 US$ 1,600.00 Feb, 2018 · 237 pages

Ask Your Question

Autism - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: